Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Brainstorm Cell (BCLI)

Brainstorm Cell (BCLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,807
  • Shares Outstanding, K 35,721
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,810 K
  • 60-Month Beta 0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.86
Trade BCLI with:

Options Overview

Details
  • Implied Volatility 171.86%
  • Historical Volatility 66.44%
  • IV Percentile 83%
  • IV Rank 27.70%
  • IV High 405.75% on 11/13/20
  • IV Low 82.23% on 08/20/20
  • Put/Call Vol Ratio 1.23
  • Today's Volume 661
  • Volume Avg (30-Day) 987
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 45,024
  • Open Int (30-Day) 26,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +3.30%
on 04/16/21
4.75 -34.11%
on 03/24/21
-1.17 (-27.21%)
since 03/16/21
3-Month
3.03 +3.30%
on 04/16/21
8.14 -61.55%
on 02/04/21
-1.97 (-38.63%)
since 01/15/21
52-Week
3.03 +3.30%
on 04/16/21
17.95 -82.56%
on 10/09/20
-2.80 (-47.22%)
since 04/16/20

Most Recent Stories

More News
Thinking about buying stock in Dolphin Entertainment, Hall of Fame Resort & Entertainment, Aptose Biosciences, Cinedigm, or Brainstorm Cell Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DLPN, HOFV, APTO, CIDM, and BCLI.

CIDM : 1.2200 (+3.39%)
DLPN : 9.15 (+1.44%)
HOFV : 3.13 (-4.28%)
APTO : 5.12 (-6.57%)
BCLI : 3.13 (-2.49%)
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS

, /PRNewswire/ -- . (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated...

BCLI : 3.13 (-2.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc.("Brainstorm" or the "Company") (NASDAQ: BCLI)....

BCLI : 3.13 (-2.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:  BCLI).  Such investors are advised to...

BCLI : 3.13 (-2.49%)
Tenax Therapeutics, Inc. Expands Board of Directors

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today...

TENX : 1.8200 (-3.70%)
RDHL : 7.10 (-3.79%)
BCLI : 3.13 (-2.49%)
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased...

BCLI : 3.13 (-2.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:  BCLI).  Such investors are advised to...

BCLI : 3.13 (-2.49%)
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI)....

BCLI : 3.13 (-2.49%)
BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference

, /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team...

BCLI : 3.13 (-2.49%)
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

NEW YORK, NY / ACCESSWIRE / February 22, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company")...

BCLI : 3.13 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

See More

Key Turning Points

3rd Resistance Point 3.43
2nd Resistance Point 3.33
1st Resistance Point 3.23
Last Price 3.13
1st Support Level 3.03
2nd Support Level 2.93
3rd Support Level 2.83

See More

52-Week High 17.95
Fibonacci 61.8% 12.25
Fibonacci 50% 10.49
Fibonacci 38.2% 8.73
Last Price 3.13
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar